Chronic Pain – Unmet Need – Detailed, Expanded Analysis – Chronic Low Back Pain (US/EU)
Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain therapy market. Prescription treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), opioid-based analgesics, antiepileptic drugs, and cytokine inhibitors. Although prescription drug-treatment rates in this population are relatively high, opportunity exists for more-potent yet safe therapies. This content provides quantitative insight into U.S. and European primary care physicians’ perceptions of the key treatment drivers and goals in the management of CLBP, the existing level of unmet need in this indication, and the remaining commercial opportunities.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for CLBP?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies such as tramadol ER (Janssen’s Ultram ER, Grünenthal’s Contramal, other brands, generics) and Duexis (Horizon Therapeutics’ ibuprofen / famotidine; in the United States) perform on key treatment drivers and goals for CLBP?
- What are the top areas of unmet need and opportunity in CLBP?
- What trade-offs in drug price and drug performance across key drug attributes are surveyed U.S. PCPs and European GPs willing to make?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. PCPs and 31 European GPs fielded in January 2020.
Key companies: Bristol-Myers Squibb, Horizon Therapeutics, Janssen, Pfizer, Purdue
Key drugs: Celecoxib, Duexis (ibuprofen / famotidine), fentanyl transdermal patch, oxycodone CR, pregabalin, tramadol ER, triamcinolone (injectable)
Table of contents
- Chronic Pain - Unmet Need - Detailed, Expanded Analysis - Chronic Low Back Pain (US/EU)
- 2020 TPP Simulator for Chronic Low Back Pain
- Executive Summary
- Introduction
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed PCPs'/GPs' Prescribing Decisions in CLBP
- Importance of Efficacy Attributes to Prescribing Decisions in CLBP: United States
- Importance of Efficacy Attributes to Prescribing Decisions in CLBP: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in CLBP: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in CLBP: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in CLBP: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in CLBP: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in CLBP: United States
- Importance of Nonclinical Factors to Prescribing Decisions in CLBP: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in CLBP: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in CLBP: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for CLBP: United States
- Overall Performance of Key Therapies for CLBP: Europe
- Mean Overall Performance of Key Therapies for CLBP: United States and Europe
- Relative Performance of Key Therapies for CLBP Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for CLBP Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for CLBP Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for CLBP Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for CLBP Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for CLBP Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for CLBP Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for CLBP Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in CLBP
- Surveyed PCPsu2019 Satisfaction with the Performance of Key Therapies for CLBP on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed GPsu2019 Satisfaction with the Performance of Key Therapies for CLBP on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed PCPs' Ascribed Level of Unmet Need Across Key Efficacy Attributes in CLBP: United States
- Surveyed GPs' Ascribed Level of Unmet Need Across Key Efficacy Attributes in CLBP: Europe
- Surveyed PCPs' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in CLBP: United States
- Surveyed GPs' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in CLBP: Europe
- Surveyed PCPs' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in CLBP: United States
- Surveyed GPs' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in CLBP: Europe
- Surveyed PCPs' Ascribed Level of Unmet Need Across Key Nonclinical Factors in CLBP: United States
- Surveyed GPs' Ascribed Level of Unmet Need Across Key Nonclinical Factors in CLBP: Europe
- Key Findings: Unmet Need in CLBP and Related Indications
- Surveyed PCPs' Ascribed Level of Unmet Need in CLBP and Related Indications: United States
- Surveyed GPs' Ascribed Level of Unmet Need in CLBP and Related Indications: Europe
- Opportunity Analysis
- Target Product Profiles
- Appendix
Bethany A. Kiernan, Ph.D., Director, Healthcare Research & Data Analytics, Infectious, Niche, and Rare Diseases. Dr. Kiernan manages and supports a team of analysts and managers producing both syndicated and custom market research analyses in a range of niche / rare indications as well as infectious diseases. Dr. Kiernan has extensive experience in market forecasting and broad knowledge across a range of CNS disorders, rare diseases, and infectious diseases. Her previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. She earned her doctorate in neurosciences from Case Western Reserve University.